The healthcare sector is undergoing rapid changes with technological advancements and scientific breakthroughs to provide quality healthcare at an affordable cost. As a part of this, healthcare is adopting new technologies and is undergoing a digital transformation. One of the leading areas under this transformation is digital pathology, which is the digitalization of pathological operations. Digital pathology has been in healthcare and research since the introduction of photographic plates. But as technology is advancing, the tools used for performing pathological operations digitally are also advancing, with improvements in accuracy, ease of use, and connectivity.

The growing prevalence of diabetes worldwide is accelerating the demand for selfmonitoring blood glucose devices and test strips. For instance, around 10% of people are suffering from diabetes related complications in the US. Diabetes has been identified as the seventh leading cause of death in the US as it is known to cause cardiovascular conditions such as heart attacks, stroke, and blood clots. Other complications associated with diabetes include kidney-related diseases and amputation of lower limbs. Therefore, regular monitoring of blood glucose levels by diabetic patients and undiagnosed individuals is critical in effectively managing this chronic condition.

Allergies or allergic diseases are caused due to hypersensitive reactions produced by the immune system to substances that are often considered harmless in general. Allergic diseases impact almost 20% of the global population. The prevalence of allergies is increasing with population, especially among children, opting to stay indoors. Hence, many researchers have started to refer to allergies as modern epidemic. This is mostly the case with food allergies that cause the highest anaphylaxis. Allergies occur when the body encounters specific substances and the immune system of the body recognizes it as a harmful substance. Such substances are termed as allergens. When allergen encounters the body through eyes, nose, skin, or ingestion, it produces an allergic response. Based on the mechanism followed during an allergic response, the allergic reactions are categorized as types I, II, III, and IV. The first three types of allergic reactions are caused by antibodies, whereas the type IV allergic reaction is caused by the lymphocytes.

Nutrition is an essential part of life, and the need for nutrition is often amplified by acute or chronic illness. Several studies indicate an estimated 30% to 50% of patients hospitalized in the US show signs of malnutrition, which can occur due to an imbalanced diet, impaired digestion or absorption of nutrition, or other medical conditions when metabolic requirements exceed intake. Malnutrition is a global problem, and studies have indicated that 40% of hospitalized elderly patients in Canada and nearly 40% of hospitalized patients in Europe suffer from malnutrition, which, if left unmanaged, can worsen morbidity, mortality, and health complications, in addition to extending hospitalization.

近日，国家联合采购办公室发布《全国药品集中采购文件（胰岛素专项）》。本次胰岛素集采，按照胰岛素的功能（餐时、基础、预混）、来源和化学结构（二代、三代）分为餐时人胰岛素、基础人胰岛素、预混人胰岛素、餐时胰岛素类似物、基础胰岛素类似物、预混胰岛素类似物，共6 个采购组。

本报告阐述多特异性药物的开发趋势、双抗作为多特异性药物之一，靶点、结构设计经验积累、投融资、人才等均有利于其发展。双抗具备高临床价值，相比目前的联合用药，具备潜在的安全性和有效性方便的提升；并且相比单抗，可以新增双靶点信号阻断、直接招募免疫细胞的功能，进一步提升疗效。国内2030年双抗行业预计规模超百亿美元。目前全球已经有正在销售的3个双抗产品，其中不乏超20亿美元以上的大品种。国内的双抗已经有35个以上进入到临床阶段，商业化转化在即。

在本篇报告中我们通过一定的筛选标准选出了多个有望通过本次医保谈判纳入目录的稀缺性较强、具备疗效优势的非肿瘤药物，主要包括注射用泰它西普（荣昌生物）、环孢素滴眼液（Ⅱ）（兴齐眼药）、阿芬太尼（人福医药）、咪达唑仑口服溶液（人福医药）、苯磺酸瑞马唑仑（人福医药）、甲苯磺酸瑞马唑仑（恒瑞医药）、海曲泊帕乙醇胺（恒瑞医药）、苹果酸奈诺沙星氯化钠注射液（浙江医药）、环泊酚注射液（海思科）等。

我们选取了311家医药上市公司（包含科创板），2021年Q1-3收入总额14054亿元，归母净利润1595亿元，分别占申 万医药全成分结果比例是：85%、90%，主要剔除了在2019、2020年、2021Q1-3提取巨额商誉减值损失的企业。2021年 Q1-3全行业收入增速为21%，归母净利润增速为27.2%。2021年Q1-3实现归母净利润正增长的公司有223家，占比 72%，84%（260/311）的公司实现收入正增长。

板块双周表现：近两周沪深300 指数下跌2.37%，医药生物（申万）指数 下跌2.85%，较沪深300 的相对收益为-0.48%，行业排名第18 位。分子板 块来看，近两周8 个申万医药子行业涨跌分化，大部分板块有所下跌。其中 SW 化学制剂、SW 医疗器械II 实现上涨，分别上涨1.86%、1.11%，其他 板块均有所下跌，其中SW 化药原料药、SW 医疗服务II 跌幅较大，分别下 跌5.76%、5.86%。整体来看，板块表现弱于大盘。

10月29日，国家药监局综合和规划财务司印发通知明确，自今年11月1日起中药配方颗粒品种实施备案管理；国家药监局发布公告明确，自今年11月1日起正式启用中药配方颗粒备案模块。早在今年2月，国家药监局等四部门就发布公告明确，将结束中药配方颗粒试点工作，中药配方颗粒品种实施备案管理。这意味着市场对所有符合条件的生产企业放开，中药配方颗粒行业进入发展新阶段。